免疫检查点抑制剂相关肝毒性  

Immune checkpoint inhibitor related hepatotoxicity

作　　者：鲁俊锋[1] 彭智[2] 朱向高[3] 陈新月[1] 郑素军[1] Lu Junfeng;Peng Zhi;Zhu Xianggao;Chen Xinyue;Zheng Sujun(The First Department of Liver Disease Center,Beijing YouAn Hospital,Capital Medical University,Beijing 100069,China;Department of Gastrointestinal Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Radiotherapy,Peking University Cancer Hospital,Beijing 100142,China)

机构地区：[1]首都医科大学附属北京佑安医院肝病中心一科,北京100069 [2]北京大学肿瘤医院暨北京市肿瘤防治研究所消化肿瘤内科,北京100142 [3]北京大学肿瘤医院暨北京市肿瘤防治研究所放疗科,北京100142

出　　处：《中国肝脏病杂志（电子版）》2021年第2期1-5,共5页Chinese Journal of Liver Diseases：Electronic Version

基　　金：“十三五”国家科技重大专项课题(2017ZX10202201、2017ZX10201201-001-008、2017ZX10302201-004、2017ZX10202203-006);北京市医院管理中心重点医学专业发展计划(扬帆计划)(ZYLX202125)。

摘　　要：近年来,免疫治疗已成为肿瘤领域的一项重大突破。免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)通过阻断免疫检查点的抑制性免疫调节作用活化T细胞,增强机体抗肿瘤免疫应答。随着ICIs的广泛应用,免疫相关不良事件(immune-related adverse events,irAEs)日益引起各科临床医师的重视。其中,ICIs诱发的免疫相关肝毒性(immune-mediated hepatotoxicity,IMH)甚至可导致肝衰竭或死亡,其发生率有逐渐升高趋势。本文针对IMH的发生、可能机制、病理以及诊治等进行综述。In recent years,immunotherapy has become a major breakthrough in the field of oncology.Immune checkpoint inhibitors(ICIs)can activate T cells and enhance the anti-tumor immune response by blocking the inhibitory immune-regulatory effects.With the wide application of ICIs,immune-related adverse events(irAEs)are increasingly concerned by multidisciplinary clinicians.The incidence of ICIs induced immune-mediated hepatotoxicity(IMH)which could lead to liver failure or death has been increasing.This article reviews the occurrence,possible mechanism,pathology,diagnosis and treatment of IMH.

关 键 词：免疫检查点抑制剂 肝毒性 

分 类 号：R979.1[医药卫生—药品]